Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.83 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.83 |
| ▸ | PLK1 | P53350 | 3/20 | 0.55 |
| ▸ | IGF1R | P08069 | 8/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092922 | 0.91 | TTK (0.88) | TTKEIF2AK3PLK1IGF1RPTK2 | |
| SCHEMBL526128 | 0.91 | TTK (0.72) | TTKEIF2AK3PLK1IGF1RPTK2 | |
| Potassium SCHEMBL14990284 | 0.91 | TTK (0.87) | TTKEIF2AK3PLK1IGF1RPTK2 | |
| SCHEMBL14990281 | 0.91 | TTK (0.87) | TTKEIF2AK3PLK1IGF1RPTK2 | |
| SCHEMBL14990330 | 0.91 | TTK (1.00) | TTKEIF2AK3IGF1RPTK2AURKA | |
| Potassium Ion SCHEMBL14990282 | 0.90 | TTK (0.86) | TTKEIF2AK3IGF1RPTK2AURKA | |
| SCHEMBL1896057 | 0.88 | TTK (0.66) | TTKEIF2AK3PLK1IGF1RAURKA | |
| SCHEMBL10092923 | 0.85 | TTK (0.82) | TTKEIF2AK3PLK1IGF1RPTK2 | |
| SCHEMBL14990342 | 0.85 | TTK (0.82) | TTKEIF2AK3PLK1IGF1RPTK2 | |
| SCHEMBL14990540 | 0.85 | TTK (1.00) | TTKEIF2AK3PLK1IGF1RPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| EP-2598508-B1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-22 | — | — | EP | disclosed |
| EP-2598508-B1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-22 | — | — | EP | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| EP-2598508-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013557-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013557-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | CSNK1A1, RPS6KA1, CSNK2A1 | TTK 341/4885EIF2AK3 315/4885PLK1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.